Skip to content
lifestyle.smarttalksuccess.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
BioInvent International
BioInvent to Participate in Upcoming Investor Conferences
November 9, 2026
Invitation to Presentation of BioInvent’s Interim Report January – September 2026
October 27, 2026
BioInvent’s BI-1808 and KEYTRUDA(R) Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer
October 24, 2026
BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026
October 18, 2026
BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research
October 15, 2026
BioInvent International AB Announces that its CFO will Retire in 2027
October 12, 2026
BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research
August 20, 2026
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer
August 7, 2026
BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models
July 28, 2026
BioInvent’s TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)
June 11, 2026
1
2
Next Page
→